August 2012
-
ReCode Therapeutics said that the Cystic Fibrosis Foundation will provide an additional $3 million for development of RCT2100 inhaled mRNA therapy for CF and that the company has closed a funding of more than $29… Read more . . .
-
Tonix Pharmaceuticals has announced plans for a Phase 2 trial of its TNX-2900 intranasal magnesium-potentiated oxytocin in patients with Prader-Willi syndrome (PWS). According to Tonix, the FDA has already cleared the company’s IND for a… Read more . . .
-
Inhaled drug developer MannKind Corporation has announced the appointment of Ajay Ahuja as Executive VP and Chief Medical Officer. Ahuja was most recently Development and Launch Leader at Kardigan Bio; his previous experience includes executive roles at… Read more . . .
-
Gossamer Bio, which is developing inhaled dry powder seralutinib, announced a deal with Samsara BioCapital giving the company an option to acquire Respira Therapeutics along with Respira’s RT234 vardenafil DPI. On signing, Gossamer will issue 2.5 million… Read more . . .
-
Inhaler testing specialist Copley Scientific has announced the appointment of Paul Martin as Head of Business Development. Martin, who has extensive experience in business development within the OINDP space, was most recently Associate Director of… Read more . . .
-
Blow Fill Seal specialist Ritedose, which offers CDMO services and produces its own inhalation solutions, has announced that it will spend $17 million to add 10,000 sq ft of laboratory space, tripling its current lab… Read more . . .
-
Acadia Pharmaceuticals has announced that the Phase 3 COMPASS PWS trial of ACP-101 carbetocin nasal spray in Prader-Willi syndrome patients with hyperphagia failed to meet any of its endpoints, including the primary endpoint of change… Read more . . .
-
Nano PharmaSolutions and CDMO Mikart have announced limited data from an ongoing Phase 1 trial of Nano PharmaSolutions’ NT-301 apomorphine nasal powder, which is in development for the treatment of OFF episodes in Parkinson’s disease.… Read more . . .
-
Polyrizon announced that it has submitted a pre-submission package to the FDA for its PL-14 Allergy Blocker nasal spray. The company describes the product as “a novel, non-invasive nasal spray that forms a physical barrier… Read more . . .
-
According to ARS Pharmaceuticals, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved 1mg and 2mg doses of neffy epinephrine nasal spray for the treatment of anaphylaxis in people who weigh more than 15 kilograms.… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.